HK Stock Market Move | Zhongshenjianye (02503) surged over 8% once, intending to acquire 100% equity of Huajian Development for approximately 213.6 million Hong Kong dollars to consolidate contracting construction engineering resources.
China Deep Construction (02503) rose more than 8% at one point, but as of the time of writing, it has risen 3.51% to 0.59 Hong Kong dollars, with a turnover of 20.03 million Hong Kong dollars.
ZHONGSHENJIANYE (02503) rose by more than 8% at one point. As of the time of writing, it has risen by 3.51% to 0.59 Hong Kong dollars, with a turnover of 20.0328 million Hong Kong dollars.
In terms of news, ZHONGSHENJIANYE announced that on November 6, 2025, the company intends to acquire 100% equity of Huajian Development Co., Ltd. from Huajian Investment Limited, Huajian Consulting Limited and Huajian Technology Limited for a total consideration of approximately 213.6 million Hong Kong dollars. The company will issue approximately 403 million shares of consideration shares at a price of 0.53 Hong Kong dollars per share to the seller or its nominee for payment. The target company is mainly engaged in investment and holding.
As part of the group's construction engineering contracting services, the group is responsible for supervising its construction projects. Considering that Huajian Engineering focuses on the field of engineering supervision, the board of directors believes that the acquisition is a good opportunity for the group to enter the field of engineering supervision and enhance its supervision capabilities. The acquisition is beneficial for integrating the group's resources in construction engineering contracting, thereby expanding its customer base and further enhancing its position and competitiveness in the construction industry.
Related Articles

SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

FIRST PACIFIC (00142) has completed the proposed demerger of MAYNILAD WATER SERVICES, INC. and will independently list on the Philippine Stock Exchange.

BOAN BIOTECH (06955): Two types of Dexu Monoclonal Antibody Injections have been accepted for market approval in the United Kingdom.
SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

FIRST PACIFIC (00142) has completed the proposed demerger of MAYNILAD WATER SERVICES, INC. and will independently list on the Philippine Stock Exchange.

BOAN BIOTECH (06955): Two types of Dexu Monoclonal Antibody Injections have been accepted for market approval in the United Kingdom.

RECOMMEND

SERES Faces Market Test in Hong Kong: Shares Open Below Issue Price Despite HK$220 Billion Market Valuation
06/11/2025

Copper Prices Surge While Former “Copper King” Who Outpaced Huawei and Tencent Falls into Decline
06/11/2025

National Energy Administration Reports New-Type Energy Storage Capacity Exceeds 100 Million Kilowatts by End‑September
06/11/2025


